A pilot study of prednisone in alzheimer’s disease

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 4, 1996, Pages 201-206

  Aisen, Paul S ^a   Marin, Deborah ^a   Attstiel, Larry ^a   Goodwin, Catherine ^a   Baruch, Bella ^a   Jacobson, Rachel ^a   Ryan, Theresa ^a   Davis, Kenneth L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute phase response; Alzheimer s disease; Glucocorticoids; Inflammation

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; C REACTIVE PROTEIN; GLUCOCORTICOID; PREDNISONE;

ACUTE PHASE RESPONSE; ADULT; AGED; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION COMPLICATION; MALE; MULTICENTER STUDY; NECK PAIN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; URINARY TRACT INFECTION;

ACUTE-PHASE PROTEINS; AGED; AGED, 80 AND OVER; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MMPI; PILOT PROJECTS; PREDNISONE;

EID: 0029817788     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106879     Document Type: Article

References (35)

1. Bauer J, Strauss S, Schreitcr-Gasser U, Gantcr U, Schlcgcl P, Witt I, Yolk B, Berger M: Inter-lcukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer’s disease cortices, FEBS Lett 1991,285:111-114.
2. Abraham CR, Selkoe DJ, Potter H: Immuno-histochemical identification of the serine pro-teasc inhibitor alpha-1 antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease, Cell 1988;52:487-501.
3. Eikelenboom P, Hack CE, Kamphorst W, Rozcmuller JM: Distribution pattern and functional state of complement proteins and tt-antichymotrypsin in cerebral β/A4 deposits in Alzheimer's disease, Res Immunol 1992; 143: 617-620.
4. rantichymo-trypsin and apolipoprotein E promote assembly of Alzheimer 5-protein into filaments, Nature 1994;372:92-94.
5. Altsticl LD, Lawlor B, Mohs R, Schmeidler J, Dalton A, Mehta P, Davis K: Elevated alpha antichymotrypsin serum levels in a subset of nondcmcnled first-degree relatives of Alzheimer's disease patients, Dementia 1995;6:17-20.
6. Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K, lshiguro K, Hari-gaya Y, Wakabayashi W: Alpha-1-antichymo-trypsin as a possible biochemical marker for Alzhcimcr-type dementia, Ann Neurol 1990; 28:561-567.
7. Brugge K, Katzman R, Hill LR, Hansen LA, Saitoh T: Serological ci-antichymotrypsin in Down's syndrome and Alzheimer’s disease, Ann Neurol 1992:32:193-197.
8. Hinds TR, Kukull WA, Van Belle G, Schcllcn-berg GD, Villacres EC, Larson EB: Relationship between serum al-antichymotrypsin and Alzheimer's disease, Neurobiol Aging 1994; 15: 21-27.
9. lshii T, Haga S: Immuno-clcctron-microscopic localization of complements in amyloid fibrils of senile plaques, Acta Neuropathol (Berl) 1984:63:296-300.
10. McGecr PL, McGeer EG: Complement proteins and complement inhibitors in Alzheimer's disease, Res Immunol 1992:143:621-624.
11. Eikelcnboom P, Hack CE, Kamphorst W, Rozcmuller JM: Distribution pattern and functional state of complete proteins and alpha-1-anlicliymotrypsin in cerebral bcta/A4 deposits in Alzheimer’s disease, Res Immunol 1992; 143:617-620.
12. McGcer PL, Itagaki S, Tago H, McGecr EG: Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR, Ncurosci Lett 1987:79:195-200.
13. Rozemuller JM, Van der Valk P, Eikelcnboom P: Activated microglia and cerebral amyloid deposits in Alzheimer's disease, Res Immunol 1992;143:646-649.
14. Haga S, Akai K, Ishii T: Demonstration of microglial cells in and around senile (ncuritic) plaques in the Alzheimer brain: an immunohis-lochemical study using a novel monoclonal antibody, Acta Neuropathol 1989:77:569-575.
15. Perlmutter LS, Scott SA, Barrón E, Chui HC: MHC class Il-posiiive microglia in human brain: Association with Alzheimer lesions, J Neurosci Res 1992;33:549-558.
16. McGcer PL, Rogers J: Medical hypothesis: antiinflammatory agents as a therapeutic approach to Alzheimer's disease, Neurology 1992;42:447-449.
17. Aisen PS, Davis KL: Inflammatory mechanisms in Alzheimer’s disease: Implications for therapy, Am J Psychiatry 1994:151:1105-1113.
18. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGecr PL, Kaszniak AW, Zalinski J, Cofield M, Mansukliani L, Willson P, Kogan F: Clinical trial of indomethacin in Alzheimer's disease, Neurology 1993;43:1609-1611.
19. Paulus HE: Nonsteroidal anti-inflammatory drugs: in Kelley WN, Harris ED, Ruddy S, Sledge CB (eds), A Textbook of Rheumatology, Philadelphia, Saunders, 1989.
20. McKhann G, Drachman D, Folstein M, Katz-ntan R, Price D, Sladlan EM: Clinical diagnosis of Alzheimer's disease: Report of the N1NCDS-ADRDA Work Group, Neurology 1984:34:939-944.
21. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RWR, Symon L: Cerebral blood flow in dementia, Arch Neurol 1975;32:632-637.
22. Folstein M, Folstein S, Mchugli P: The Mini-Mental State Examination, J Psychiatr Res 1975;12:189-198.
23. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease, Am J Psychiatry 1984;141:1356-1364.
24. Hamilton M: A rating scale for depression, J Neurol Ncurosurg Psychiatry 1960:23:56-62.
25. Blessed G, Tomlinson BE, Roth M: The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects, Br J Psychiatry 1968;114:797-811.
26. Kuiper MA, Van Kamp GJ, Bergmans PLM, Scheltcns P, Wolters EC: Scrum ai-antichymo-trypsin is not a useful marker for Alzheimer’s disease or dementia in Parkinson’s disease, J Neural Transm Park Dis Dement Sect 1993:6: 145-149.
27. Pirttila T, Mehta PD, Frey H, Wisniewski HM: Alpha-l-antichymotrypsin and lL-l-bcta are not increased in CSF or scrum in Alzheimer's disease, Neurobiol Aging 1994; 15:313-317.
28. Abraham CR, Shirahama T, Potter H: The pro-lease inhibitor tq-antichymotrypsin is associated solely with amyloid deposits containing the ß-protein and is localized in specific cells of both normal and diseased brain, Neurobiol Aging 1990;11:123-129.
29. Vandcnabecle P, Ficrs W: Is amyloidogencsis during Alzheimer's disease due to an 1L-I/IL-6-mcdiatcd ‘acute phase response’ in the brain? ImmunolToday 1991;12:217-219.
30. Ballou SP, Kushnerl: Laboratory’evaluation of inflammation; in Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (eds): Textbook of Rheumatology, Philadelphia, Saunders, 1993, pp 671-679.
31. McEwen BS, Angulo J, Cameron H, Chao HM, Daniels D, Gannon MN, Gould E, Mcndelson S, Sakai R, Spencer R, Woolley C: Paradoxical effects of adrenal steroids on the brain: Protection versus degeneration, Biol Psychiatry 1992; 31:177-199.
32. Starkman MN, Gebarski SS, Bcmct S, Schtcin-gart DE: Hippocampal formation volume, memory dysfunction and cortisol levels in patients with Cushing’s syndrome, Biol Psychiatry 1992;32:756-765.
33. Wolkowitz OM, Reus VI, Weingartner H, Thompson K, Breier A, Doran A, Rubinow D, Pickar D: Cognitive effects of corticosteroids, Am J Psychiatry 1990;147:1297-1303.
34. Newcomer JW, Craft S, Hcrshcy T, Askins K, Bardgetl ME: Glucocorticoid-induced impairment in declarative memory performance in adult humans, J Neurosci 1994:14:2047-2053.
35. Denburg SD, Carbone RM, Denburg JD: Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus, Arthritis Rheum 1994;37.1311-1320.